Paul J. Gokhale

Paul J. Gokhale

Auto-generated profile, based on publicly available information

Paul J. Gokhale

The University of Sheffield

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2003 in Nature Biotechnology
Verified
Journal Article
Closed access
JDJonathan S Draper
Jonathan S Draper
KSKath Smith
Kath Smith
PGPaul Gokhale
Paul Gokhale
HMHarry D Moore
Harry D Moore
EMEdna Maltby
Edna Maltby
PAPeter W Andrews
Peter W Andrews

13 September 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
TETariq Enver
Tariq Enver
SSShamit Soneji
Shamit Soneji
CJChirag Joshi
Chirag Joshi
JBJohn Brown
John Brown
Francisco José IborraFrancisco José Iborra
Francisco José Iborra
PAPeter W. Andrews
Peter W. Andrews
Human embryonic stem cell (HESC) lines vary in their characteristics and behaviour not only because they are derived from genetically outbred populations, but also because they may undergo progressive adaptation upon long-term culture in vitro . Such adaptation may reflect selection of variants with altered propensity for survival and retention of an undifferentiated phenotype. Elucidating the mechanisms involved will be important for understanding normal self-renewal and commitment to differentiation and for validating the safety of HESC-based therapy. We have investigated this process of adaptation at the cellular and molecular levels through a comparison of early passage (normal) and late passage (adapted) sublines of a single HESC line, H7. To account for spontaneous differentiation that occurs in HESC cultures, we sorted cells for SSEA3, which marks undifferentiated HESC. We show that the gene expression programmes of the adapted cells partially reflected their aberrant karyotype, but also resulted from a failure in X-inactivation, emphasizing the importance in adaptation of karyotypically silent epigenetic changes. On the basis of growth potential, ability to re-initiate ES cultures and global transcription profiles, we propose a cellular differentiation hierarchy for maintenance cultures of HESC: normal SSEA3+ cells represent pluripotent stem cells. Normal SSEA3− cells have exited this compartment, but retain multilineage differentiation potential. However, adapted SSEA3+ and SSEA3− cells co-segregate within the stem cell territory, implying that adaptation reflects an alteration in the balance between self-renewal and differentiation. As this balance is also an essential feature of cancer, the mechanisms of culture adaptation may mirror those of oncogenesis and tumour progression.

11 September 2008 in Stem Cells
Verified
Journal Article
Open access
PDF file
YAYaser Atlasi
Yaser Atlasi
SMSeyed Javad Mowla
Seyed Javad Mowla
SZSeyed A.M. Ziaee
Seyed A.M. Ziaee
PGPaul J. Gokhale
Paul J. Gokhale
PAPeter W. Andrews
Peter W. Andrews
OCT4 is a master regulator of self-renewal in embryonic stem cells and can potentially encode two spliced variants, designated OCT4A and OCT4B. We have examined the expression pattern of these OCT4 isoforms in various human pluripotent and nonpluripotent cells. Our data revealed that whereas OCT4A expression is restricted to embryonic stem (ES) and embryonal carcinoma (EC) cells, OCT4B can be detected in various nonpluripotent cell types. Furthermore, we detected a novel OCT4 spliced variant, designated OCT4B1, that is expressed primarily in human ES and EC cells and is downregulated following their differentiation. We also found a significantly higher level of OCT4B1 expression in stage-specific embryonic antigen-3 (SSEA3)(+) compared with SSEA3(−) subpopulations of cultured ES cells. Taken together, our data demonstrated a distinctive expression pattern for OCT4 spliced variants in different cell types and highlight the necessity of defining the type of OCT4 when addressing the expression of this gene in different human cells. Disclosure of potential conflicts of interest is found at the end of this article.

26 February 2010 in In Vitro Cellular & Developmental Biology - Animal
Verified
Journal Article
Open access
PDF file
TCThe International Stem Cell Initiative Consortium
The International Stem Cell Initiative Consortium
VAVeronika Akopian
Veronika Akopian
PAPeter W. Andrews
Peter W. Andrews
SBStephen Beil
Stephen Beil
NBNissim Benvenisty
Nissim Benvenisty
HSHirofumi Suemori
Hirofumi Suemori
There are many reports of defined culture systems for the propagation of human embryonic stem cells in the absence of feeder cell support, but no previous study has undertaken a multi-laboratory comparison of these diverse methodologies. In this study, five separate laboratories, each with experience in human embryonic stem cell culture, used a panel of ten embryonic stem cell lines (including WA09 as an index cell line common to all laboratories) to assess eight cell culture methods, with propagation in the presence of Knockout Serum Replacer, FGF-2, and mouse embryonic fibroblast feeder cell layers serving as a positive control. The cultures were assessed for up to ten passages for attachment, death, and differentiated morphology by phase contrast microscopy, for growth by serial cell counts, and for maintenance of stem cell surface marker expression by flow cytometry. Of the eight culture systems, only the control and those based on two commercial media, mTeSR1 and STEMPRO, supported maintenance of most cell lines for ten passages. Cultures grown in the remaining media failed before this point due to lack of attachment, cell death, or overt cell differentiation. Possible explanations for relative success of the commercial formulations in this study, and the lack of success with other formulations from academic groups compared to previously published results, include: the complex combination of growth factors present in the commercial preparations; improved development, manufacture, and quality control in the commercial products; differences in epigenetic adaptation to culture in vitro between different ES cell lines grown in different laboratories.

23 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
OTOliver Thompson
Oliver Thompson
FMFerdinand von Meyenn
Ferdinand von Meyenn
ZHZoe Hewitt
Zoe Hewitt
JAJohn Alexander
John Alexander
AWAndrew Wood
Andrew Wood
PAPeter W. Andrews
Peter W. Andrews
The occurrence of repetitive genomic changes that provide a selective growth advantage in pluripotent stem cells is of concern for their clinical application. However, the effect of different culture conditions on the underlying mutation rate is unknown. Here we show that the mutation rate in two human embryonic stem cell lines derived and banked for clinical application is low and not substantially affected by culture with Rho Kinase inhibitor, commonly used in their routine maintenance. However, the mutation rate is reduced by >50% in cells cultured under 5% oxygen, when we also found alterations in imprint methylation and reversible DNA hypomethylation. Mutations are evenly distributed across the chromosomes, except for a slight increase on the X-chromosome, and an elevation in intergenic regions suggesting that chromatin structure may affect mutation rate. Overall the results suggest that pluripotent stem cells are not subject to unusually high rates of genetic or epigenetic alterations.

1 December 2005 in Biochemical Society Transactions
Verified
Journal Article
Closed access
MMMaryam M. Matin
Maryam M. Matin
PAP.W. Andrews
P.W. Andrews
ABA.R. Bahrami
A.R. Bahrami
IDI. Damjanov
I. Damjanov
PGP. Gokhale
P. Gokhale
JDJ.S. Draper
J.S. Draper
Embryonal carcinoma (EC) cells are the stem cells of teratocarcinomas, and the malignant counterparts of embryonic stem (ES) cells derived from the inner cell mass of blastocyst-stage embryos, whether human or mouse. On prolonged culture in vitro, human ES cells acquire karyotypic changes that are also seen in human EC cells. They also 'adapt', proliferating faster and becoming easier to maintain with time in culture. Furthermore, when cells from such an 'adapted' culture were inoculated into a SCID (severe combined immunodeficient) mouse, we obtained a teratocarcinoma containing histologically recognizable stem cells, which grew out when the tumour was explanted into culture and exhibited properties of the starting ES cells. In these features, the 'adapted' ES cells resembled malignant EC cells. The results suggest that ES cells may develop in culture in ways that mimic changes occurring in EC cells during tumour progression.